Latest Australian Taxation News

Page 2 of 22
Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.
Victor Sage
Victor Sage
30 Oct 2026
Mantle Minerals is changing the geological model at Carlton Hill, moving away from shallow stratiform targets towards potentially structurally controlled zinc-lead and copper mineralisation. The explorer ended September with A$5.232 million in cash and says its current spending rate represents 31.59 quarters of funding.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Australian Gold and Copper has expanded the high-grade Evergreen discovery in NSW while pushing towards an initial mineral resource estimate. The exploration momentum is substantial, but the company’s reported 1.93-quarter funding runway puts future drilling and financing firmly on the agenda.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
8common remained EBITDA and operating-cashflow positive in the September quarter, even as revenue fell 7.8% year on year. Its $1.9 million Australian Taxation Office contract is yet to contribute revenue, with implementation expected to begin in January.
Victor Sage
Victor Sage
29 Oct 2026
AVADA Group’s FY27 first-quarter customer receipts rose 38% to A$66.4 million, but cash conversion remained tight after A$5.1 million in Payday Super and prior-period ATO payments. The traffic management operator ended September with A$3.31 million in cash and A$13.84 million of unused facilities.
Victor Sage
Victor Sage
29 Oct 2026
Tinybeans has delivered a US$65,000 adjusted EBITDA profit and its fourth consecutive quarter of positive operating cash flow, with revenue rising 35% to US$1.60 million. The result came as subscription revenue climbed 74%, although customer acquisition costs increased across both platforms.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.
Ada Torres
Ada Torres
28 Oct 2026
Radiopharm Theranostics has received an $8 million advance against its anticipated FY26 Australian R&D tax incentive, giving the clinical-stage company additional funding for trials and working capital. The facility carries commercial interest and must be repaid by 26 October 2027.
Victor Sage
Victor Sage
26 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
FAR’s remaining value is tied largely to Woodside’s Sangomar production and oil prices, with up to US$19.8 million still potentially payable after a US$23.7 million provisional receipt. The oil and gas company ended September with US$1.73 million in unaudited cash and no exploration expenditure.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive